Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
OBJECTIVE
A multicentre study was undertaken to determine the value of somatostatin receptor (sst) scintigraphy in predicting hormonal and visual responses to octreotide treatment in GH-secreting and non-functioning pituitary adenomas.


METHODS
Somatostatin receptor scintigraphy was performed in 48 patients (19 acromegaly, 29 non-functioning pituitary adenomas with ophthalmological defects). Results were expressed as an uptake index of the pituitary area. A threshold for positivity was determined in 23 subjects considered as controls. Thirty-five patients were treated for 1 month with octreotide (300 micrograms daily). The therapeutic response was assessed on GH and IGF-I suppression or evolution of the ophthalmological defects. The relationships between the somatostatin receptor scintigraphy result, the therapeutic effect of octreotide and in vitro studies performed in 12 tumours were studied.


RESULTS
From the results of control subjects the uptake index threshold for positivity was 2. In patients, somatostatin receptor scintigraphy was positive in 64% and there was no relationship between uptake index and tumour size. In GH tumours, somatostatin receptor scintigraphy was positive in 68%; uptake index was related to octreotide-induced GH and IGF I suppression. The positive predictive value was 100% and the negative predictive value was 50%. In vitro studies showed detectable binding sites for somatostatin with sst2 and sst5 expression in the 4 GH tumours studied although somatostatin receptor scintigraphy was negative in 2 cases. In non-functioning pituitary adenomas somatostatin receptor scintigraphy was positive in 62%. Based on visual effects, the positive predictive value was 61% and the negative predictive value was 100%. A wide distribution of somatostatin binding sites was found in 8 non-functioning pituitary adenomas with expression of sst2 only.


CONCLUSIONS
In the conditions of the study, in patients with acromegaly, positive somatostatin receptor scintigraphy predicts a hormonal response but the value of somatostatin receptor scintigraphy is limited by its low negative predictive value. In patients with non-functioning pituitary adenomas, negative somatostatin receptor scintigraphy predicts that there will be no visual improvement during octreotide treatment.
Broson-Chazot
F
F
Centre de Médecine Nucléaire, Lyon, France.
Houzard
C
C
Ajzenberg
C
C
Nocaudie
M
M
Duet
M
M
Mundler
O
O
Marchandise
X
X
Epelbaum
J
J
Gomez De Alzaga
M
M
Schäfer
J
J
Meyerhof
W
W
Sassolas
G
G
Warnet
A
A
D000172:Acromegaly / Q000000981:diagnostic imaging / Q000188:drug therapy; D000236:Adenoma / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism; D011237:Predictive Value of Tests; D011379:Prognosis; D011877:Radionuclide Imaging; D017481:Receptors, Somatostatin / Q000032:analysis*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects
D000970:Antineoplastic Agents; D017481:Receptors, Somatostatin; D013006:Growth Hormone; D015282:Octreotide